Zanubrutinib Active Not Recruiting Phase 3 Trials for Waldenström's Macroglobulinemia (WM) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03053440A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)